Toulouse, 26 September 2023 – GTP Bioways, a contract development and manufacturing organisation (CDMO) specialising in the production of biotherapies, strengthens its manufacturing capacities with the opening of a new microbial bioproduction unit.
This new unit supplements the two existing bioproduction lines which cater for the manufacturing of biotherapies in mammalian cells. With the launch of this new line, GTP Bioways is now able to support biopharmaceutical companies through the pre-clinical and clinical development of any type of therapeutic protein.
GTP Bioways General Manager Eric Devic says: ‘GTP Bioways is the only French CDMO offering biotherapies manufacturing services in the microbial system. This new unit will allow us to respond to the demand of European biopharmaceutical companies who struggle to find available slots for the production of their clinical batches.’
The unit was established thanks to bold investments made over the last two years. It was part-funded through the France 2030 investment programme which saw GTP Bioways be awarded a grant under the ‘Capacity Building’ call for projects.
GTP Bioways strengthens its biotherapeutics manufacturing capacities thanks to the launch of its microbial manufacturing line
(Photo credit: Arnaud Späni)
GTP Bioways President Alain Sainsot adds: ‘The launch of this bioproduction line is perfectly aligned with the government’s ambition to increase France’s sovereignty in the field of biopharmaceutical manufacturing. Over 20 new positions have already been created in Toulouse, which demonstrates our contribution to the sector’s development.’
Several agreements have already been signed for the manufacturing of proteins for therapeutic and vaccine applications, with the first batches to come out in the autumn.
About GTP Bioways
GTP Bioways is a CDMO (Contract Development and Manufacturing Organisation) specialised in the manufacturing of biodrugs. Thanks to its integrated services, GTP Bioways supports biopharmaceutical companies from pre-clinical trials through to the commercial manufacturing of their innovative therapies.
GTP Bioways’ expertise and capabilities include process development and the mammalian and microbial based manufacturing of biological molecules, antibody-drug conjugates and nanodrugs.
GTP Bioways operates four production sites in France and employs 150 staff. Its projected turnover in 2023 is 20 million euros.
Press contacts
Charline Baraban – charline.baraban@gtp-bioways.com – +33 7 71 18 64 73
Séverine Hountondji – severine.hountondji@gtp-bioways.com
